JP6356160B2 - ネオセプチン：低分子アジュバント - Google Patents

ネオセプチン：低分子アジュバント Download PDF

Info

Publication number
JP6356160B2
JP6356160B2 JP2015559275A JP2015559275A JP6356160B2 JP 6356160 B2 JP6356160 B2 JP 6356160B2 JP 2015559275 A JP2015559275 A JP 2015559275A JP 2015559275 A JP2015559275 A JP 2015559275A JP 6356160 B2 JP6356160 B2 JP 6356160B2
Authority
JP
Japan
Prior art keywords
mmol
etoac
group
equiv
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015559275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513128A5 (cg-RX-API-DMAC7.html
JP2016513128A (ja
Inventor
ブルース ボイトラー
ブルース ボイトラー
デイル エル ボガー
デイル エル ボガー
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート, ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム, ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2016513128A publication Critical patent/JP2016513128A/ja
Publication of JP2016513128A5 publication Critical patent/JP2016513128A5/ja
Application granted granted Critical
Publication of JP6356160B2 publication Critical patent/JP6356160B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2015559275A 2013-02-25 2014-02-25 ネオセプチン：低分子アジュバント Expired - Fee Related JP6356160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768712P 2013-02-25 2013-02-25
US61/768,712 2013-02-25
PCT/US2014/018380 WO2014131023A1 (en) 2013-02-25 2014-02-25 Neoseptins: small molecule adjuvants

Publications (3)

Publication Number Publication Date
JP2016513128A JP2016513128A (ja) 2016-05-12
JP2016513128A5 JP2016513128A5 (cg-RX-API-DMAC7.html) 2017-04-06
JP6356160B2 true JP6356160B2 (ja) 2018-07-11

Family

ID=51391916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015559275A Expired - Fee Related JP6356160B2 (ja) 2013-02-25 2014-02-25 ネオセプチン：低分子アジュバント

Country Status (7)

Country Link
US (1) US9649373B2 (cg-RX-API-DMAC7.html)
EP (1) EP2958889B1 (cg-RX-API-DMAC7.html)
JP (1) JP6356160B2 (cg-RX-API-DMAC7.html)
CN (1) CN105339346B (cg-RX-API-DMAC7.html)
AU (1) AU2014218598B2 (cg-RX-API-DMAC7.html)
CA (1) CA2902342C (cg-RX-API-DMAC7.html)
WO (1) WO2014131023A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
EP3747508B1 (en) 2015-03-10 2021-10-13 Ascenta Pharmaceuticals, Ltd. Dna alkylating agents for use in the treatment of cancer
WO2016161342A2 (en) * 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
EP3313385B8 (en) 2015-06-24 2021-04-21 ImmunoGenesis, Inc. Aziridine containing dna alkylating agents
US20180327364A1 (en) * 2015-11-13 2018-11-15 Brandeis University Mtor inhibitors and methods of use thereof
AU2017290238B2 (en) * 2016-06-29 2021-02-18 The Board Of Regents Of The University Of Texas System Diprovocims: a new and potent class of TLR agonists
WO2019099578A1 (en) 2017-11-14 2019-05-23 Chidren's Medical Center Corporation Use of imidazopyrimidine for modulating human immune response
JP7304855B2 (ja) 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031083A (en) 1975-10-24 1977-06-21 Yeda Research And Development Co., Ltd. Cephalosporin antibiotics
US4045438A (en) 1975-10-24 1977-08-30 Yeda Research And Development Co. Ltd. Cephalosporin antibiotics
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
CN103012304B (zh) * 2005-06-30 2014-07-23 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
EP2043672A4 (en) * 2006-07-07 2009-10-21 Univ Leland Stanford Junior SELECTIVE INHIBITORS OF CASPASES
SI2510946T1 (sl) * 2007-02-07 2015-12-31 The Regents Of The University Of California Konjugati sintetičnih agonistov TLR in njihove uporabe
JP5380465B2 (ja) * 2008-03-03 2014-01-08 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010088395A2 (en) * 2009-01-30 2010-08-05 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9

Also Published As

Publication number Publication date
CN105339346A (zh) 2016-02-17
EP2958889B1 (en) 2017-03-22
US9649373B2 (en) 2017-05-16
EP2958889A1 (en) 2015-12-30
CA2902342A1 (en) 2014-08-28
US20160000907A1 (en) 2016-01-07
AU2014218598B2 (en) 2016-08-04
WO2014131023A1 (en) 2014-08-28
CN105339346B (zh) 2017-03-08
EP2958889A4 (en) 2016-07-27
AU2014218598A1 (en) 2015-09-10
CA2902342C (en) 2017-10-17
JP2016513128A (ja) 2016-05-12

Similar Documents

Publication Publication Date Title
JP6356160B2 (ja) ネオセプチン：低分子アジュバント
EP1408986B1 (en) Proteomimetic compounds and methods
CN104080768B (zh) 作为mgat2抑制剂的芳基二氢吡啶酮及哌啶酮
CN108697715A (zh) 包含帽依赖性核酸内切酶抑制剂及抗流感药的组合的流感治疗用药物
CN110494141A (zh) 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
CN111032034A (zh) 螺环化合物及其制造和使用方法
TW201605775A (zh) 芳基醚及其用途
KR20140014399A (ko) 사람 면역결핍 바이러스 복제 억제제
CN105339350B (zh) 二氢吡啶酮mgat2抑制剂
TWI689487B (zh) 經取代雙環化合物
JP2016518317A (ja) 二環式鎮痛化合物
CN105492075B (zh) 病毒复制抑制剂、它们的制备方法和它们的治疗用途
KR20180037947A (ko) 글리코피로늄 지방산 염 및 이의 제조방법
CN114230512A (zh) 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
JP2017530943A (ja) Ｔｌｒ非依存性低分子アジュバント
WO2025026209A1 (zh) Arf1抑制剂及其应用
CN116284215B (zh) 一种ezh2配体protac衍生物及其制备方法和用途
WO2023061263A1 (zh) Shp2抑制剂、包含其的药物组合物及其用途
WO2024141011A1 (zh) 补体因子b抑制剂及其药物组合物和应用
WO2011150682A1 (zh) 4-羟基喹啉-3-酰胺衍生物及其制备方法和用途
HK1217457B (zh) 病毒复制抑制剂、它们的制备方法和它们的治疗用途
HK1105963A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
HK1175656B (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
HK1175656A (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170224

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170224

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170605

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180613

R150 Certificate of patent or registration of utility model

Ref document number: 6356160

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees